| Literature DB >> 25875121 |
Tom Clifford1, Glyn Howatson2,3, Daniel J West4, Emma J Stevenson5.
Abstract
In recent years there has been a growing interest in the biological activity of red beetroot (Beta vulgaris rubra) and its potential utility as a health promoting and disease preventing functional food. As a source of nitrate, beetroot ingestion provides a natural means of increasing in vivo nitric oxide (NO) availability and has emerged as a potential strategy to prevent and manage pathologies associated with diminished NO bioavailability, notably hypertension and endothelial function. Beetroot is also being considered as a promising therapeutic treatment in a range of clinical pathologies associated with oxidative stress and inflammation. Its constituents, most notably the betalain pigments, display potent antioxidant, anti-inflammatory and chemo-preventive activity in vitro and in vivo. The purpose of this review is to discuss beetroot's biological activity and to evaluate evidence from studies that specifically investigated the effect of beetroot supplementation on inflammation, oxidative stress, cognition and endothelial function.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25875121 PMCID: PMC4425174 DOI: 10.3390/nu7042801
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Overview of potentially bioactive compounds in beetroot (based on data from [1,2,20]).
Figure 2A comparison of the 2,2-diphenyl-1-picrylhydrazyl (DPPH•) inhibiting capacity (%) exhibited by 10 popular fruit and vegetable beverages available in the UK (values based on data from [56,57]).
Figure 3The free radical antioxidant power (FRAP) of 10 commercially available fruit and vegetable beverages post a simulated in vitro model of human digestion (values based on data from [56,57]).
Overview of human and animal studies investigating the effects of beetroot and its derivatives on oxidative stress and inflammation.
| Authors | Cohort under Investigation | Dosage | Antioxidant Capacity of Treatment | Duration | Toxic inducing Protocol | Inflammation | Oxidative Stress | Enzymatic Antioxidant Activity |
|---|---|---|---|---|---|---|---|---|
| [ | 48 male wistar rats | Beetroot juice delivered by gavage (8 mL∙kg∙bm∙day−1; ≈1.92 mL∙day−1) | 23.5 μmol Trolox equivalents∙mL−1 | 28 days | Intraperitoneal injection of CCl4 (2 mL∙kg∙bm−1) or NDEA (150 mL∙kg∙bm−1) | N/A | TBARS ↓ PC ↓ DNA damage ↓ | SOD ↑ GPX ↑ CAT ↑ GR ↑ |
| [ | 80 male ICR mice | Betalains from beetroot delivered orally (0, 5, 20 and 80 mg∙kg∙bm∙day−1; ≈0–1.44 mg∙day−1) | N/A | 30 days | Exposed to cobalt-60-γ-gamma radiation (6.0 Gy, 1.5 Gy min−1) | N/A | MDA ↓ | SOD ↑ CAT ↑ GSH ↑ |
| [ | 24 male wistar rats | Beetroot juice delivered by gavage (8 mL∙kg∙bm∙day−1) | N/A | 28 days | Intraperitoneal injection of NDEA (150 mL∙kg∙bm−1) | LDH ↓ AST ↓ ALT ↓ | DNA damage ↓ | GST ↑ |
| [ | 10 osteoarthritic patients | Capsules made from beetroot extract delivered orally (70–200 mg∙day−1) | N/A | 10 days | N/A | TNF-α ↓ IL-6 ↓ RANTES ↓ GRO-α ↓ | AOPP ↓ | N/A |
| [ | 48 albino wistar rats | Beetroot pomace extract delivered intraperitoneally (1–3 mL∙kg∙bm∙day−1; ≈0.2–0.6 ml∙day−1) | N/A | 7 days | Intraperitoneal injection of CCl4 (2 mL∙kg∙bm−1) | N/A | MDA ↓ | GSH ↑ GSHPx ↑ GR ↑ CAT ↑ |
| [ | 24 albino wistar rats | Extracts of fresh beetroot delivered orally (250 and 500 mg∙kg∙bm∙day−1; ≈45–90 mg∙day−1) | 90.1% radical inhibition in the DPPH• assay (500 μg∙mL−1) | 28 days | Intraperitoneal injection of gentamicin (8 mg∙kg∙bm−1 for 8 days) | IL-6 ↓ TNF-α ↓ MPO ↓ NF-κB ↓ | MDA ↓ | CAT ↑ NP-SH ↑ |
| [ | 24 female Sprague-dawley rats | Beetroot juice delivered by gavage (8 mL∙kg∙bm∙day−1; ≈1.92 mL∙day−1) | N/A | 28 days | Intraperitoneal injection of DMBA (10 mg∙kg∙bm−1 for 2 days) | LDH ↓ ALT↓ | N/A | GST ↑ NQO1 ↑ |
NDEA, N-nitrosodiethylamine; GST, glutathione S-transferase; RANTES, regulated upon activation normal T cell growth; GRO-α, regulated oncogene-alpha; CCl4 carbon tetrachloride; GSH, reduced glutathione; GSHPx, glutathione peroxidase; GR, glutathione reductase; GPX, glutathione peroxidase; TNF-α, tumour necrosis factor-alpha; TBARS, thiobarbituric acid reactive species; PC, protein carbonyls; SOD, superoxide dismutase; ICR, imprinting control region; MDA, Malondialdehyde; CAT, catalase; AOPP, advanced oxidation protein products; IL-6, interleukin-6. Gy, gray unit; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; MPO, myeloperoxidase. NF-κB, nuclear factor kappa B; NP-SH, non-protein sulfhydryl; DMBA, 7,12-dimethylbenz[a]anthracene; NQO1, NAD(P)H dehydrogenase [quinone] 1.
Figure 4Illustration of the inflammatory cascade in response to cellular attack and possible pathways where betalains may exhibit inhibitory effects. PGF2, Prostaglandin F2; PGE2, Prostaglandin E2; COX ½, Cyclooxygenase 1 and 2; LOX, lipoxygenase; LOX-5, 5-lipoxygenase; LOX-12, 12- lipoxygenase; HOCI, Hypochlorous acid; OH•, Hydroxyl radical; NF-κB, Nuclear Factor-Kappa B; AP-1, Activator protein 1; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-1β, Interleukin-1 beta; TNF-α, tumour necrosis factor-alpha.